Thermo Fisher Scientific TSLP Monoclonal Antibody (eBio28F12 (28F12)), Functional Grade, eBioscience

Applications

Tested Dilution

Publications

ELISA (ELISA)

-

View 1 publication 1 publication

Neutralization (Neu)

Assay-Dependent

View 1 publication 1 publication

Functional Assay (Functional)

Assay-Dependent

View 3 publications 3 publications

Product Specifications

Published species

Mouse

Host/Isotype

Rat / IgG2a, kappa

Recommended Isotype Control

Rat IgG2a kappa Isotype Control (eBR2a), Functional Grade, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

eBio28F12 (28F12)

Conjugate

Functional Grade Functional Grade Functional Grade

Form

Liquid

Concentration

1 mg/mL

Storage conditions

4° C

Shipping conditions

Wet ice

RRID

AB_2866028

Product Specific Information

Description: The monoclonal antibody eBio28F12 reacts with and inhibits the bioactivity of mouse TSLP. Thymic Stromal-Derived Lymphopoetin (TSLP) was first identified in the tissue culture supernatant of a thymic stromal cell line as a growth factor capable of inducing proliferation and differentiation of pre-B cells. It was later found to be closely related to another stromal cytokine, IL-7, with which it shares overlapping functions. Along with its proliferative effects on B cells, TSLP induces dendritic cells to support the differentiation of naive T cells towards the Th2 lineage and may also be involved in the development of CD4^+CD25^+ regulatory T cells. The receptor for TSLP is heterodimeric and shares one subunit, IL-7Ralpha, with IL-7 and other members of the family, while the TSLPR subunit is unique to TSLP.

TSLP expression can be induced by a variety of inflammatory cytokines and TLR ligands. Expression is regulated by NF-kappaB and has been detected in epithelial cells, stromal cells, and basophils. Elevated levels of TSLP are associated with asthma and atopic dermatitis, which are both Th2-mediated inflammatory conditions. It is believed that chronic overexpression of TSLP may result in increased sensitivity to allergens, resulting in susceptibility to these conditions.

Applications Reported: The monoclonal antibody eBio28F12 reacts with and inhibits the bioactivity of mouse TSLP.

Applications Tested: The ND50 of eBio28F12, as determined by the neutralization of recombinant mouse TSLP-induced proliferation of the Nag8/7 cell line, is 1-3 ng/mL in the presence of 0.5 ng/mL mTSLP. The neutralization dose of this antibody will vary depending on cell type, assay method, and cytokine concentration.

Storage and handling: Use in a sterile environment.

Filtration: 0.2 µm post-manufacturing filtered.

Purity: Greater than 90%, as determined by SDS-PAGE.

Endotoxin Level: Less than 0.001 ng/µg antibody, as determined by LAL assay.

Aggregation: Less than 10%, as determined by HPLC.

Target Information

TSLP is a 159 amino acid four helix-bundle hemopoietic cytokine that signals through a heterodimeric receptor complex consisting of the human TSLP receptor and the IL-7R alpha-chain. It impacts myeloid cells and induces the release of T cell-attracting chemokines from monocytes, enhances the maturation of CD11c (+) dendritic cells, naive CD4 (+), and CD8 (+) T cells into proallergic effectors, and primes dendritic cells to produce large amounts of IL-12 after CD40 ligand stimulation. TSLP influences the regulation of the positive selection of regulatory T cells and maintenance of peripheral CD4 (+) T cell homeostasis. It induces allergic inflammation by directly activating mast cells and may be involved in the pathophysiology of inflammatory arthritis. It is expressed in heart, liver and prostate.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.